Amplify Weight Loss Drug & Treatment ETF holds a quantitatively derived Neutral Morningstar Medalist Rating. The rating suggests the model does not express a clear expectation of outperformance or underperformance relative to peers over a full market cycle.
Amplify Weight Loss Drug & Treatment ETF THNR
Morningstar’s Analysis THNR
Will THNR outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 66.1
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
Eli Lilly and Co | 11.34 | 643,407 | Healthcare |
Novo Nordisk AS ADR | 8.85 | 502,234 | Healthcare |
Amgen Inc | 6.17 | 350,368 | Healthcare |
Roche Holding AG Ordinary Shares new | 5.98 | 339,221 | Healthcare |
AbbVie Inc | 5.81 | 329,464 | Healthcare |
AstraZeneca PLC | 5.72 | 324,849 | Healthcare |
Pfizer Inc | 5.72 | 324,592 | Healthcare |
Gilead Sciences Inc | 5.66 | 321,189 | Healthcare |
Regeneron Pharmaceuticals Inc | 5.41 | 306,915 | Healthcare |
Chugai Pharmaceutical Co Ltd | 5.40 | 306,368 | Healthcare |